Washington6 per 100,000 GLP-1 patients developed optic neuropathy.

The new label covers all dozen GLP-1 drugs, including Ozempic, Wegovy, Zepbound and Mounjaro.

The US drug regulator’s analysis of more than 125 trials found under 4 per 100,000 on placebo or other glucose-lowering drugs.

The regulator says reduced blood flow to the optic nerve is involved, but the underlying cause is not understood.

Patients with blurred vision or blind spots should contact a clinician immediately, it said.

How each outlet framed it

drawn from 100+ reports worldwide

NDTV
gives the FDA's rate figures: about 6 per 100,000 GLP-1 users a year versus under 4 per 100,000 on placebo or other diabetes drugs

Sources: NDTV